FDA OKs Bristol Augtyro, Tyrosine Kinase Inhibitor for Solid Tumors

 Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors, demonstrating clinically meaningful response rates in the TRIDENT-1 trial1

This accelerated approval marks the second indication for Augtyro in the U.S

https://www.businesswire.com/news/home/20240604316506/en/